The clinical history of CRISPR is short. The first CRISPR-based therapy received approval in late 2023 for sickle cell disease and transfusion-dependent beta-thalassemia. Less than three years later, the technology has moved from a single approved indication to a clinical pipeline spanning dozens of conditions, with several therapies already in late-stage trials.
For physicians who don't work in genetic medicine, the pace can be hard to track. Here's a working snapshot of where things stand and what's clinically actionable.
The technology, briefly
CRISPR — Clustered Regularly Interspaced Short Palindromic Repeats — is a gene-editing system originally adapted from a bacterial immune mechanism. The clinical use case is precise: an enzyme guided by an RNA sequence to cut DNA at a specific location, which can disable a gene, correct a mutation, or insert new genetic material.
The 2023 approval was significant for two reasons. First, it demonstrated that ex vivo gene editing — modifying cells outside the body and reinfusing them — could deliver durable clinical benefit in inherited disease. Second, it established a regulatory pathway. Subsequent CRISPR therapies are being evaluated against a known framework rather than entirely new ground.
For background, the NIH maintains accessible primers on gene-editing technology, and primary research appears regularly in Nature and The New England Journal of Medicine.
What's actually approved
As of 2026, the approved CRISPR therapy landscape remains relatively narrow but is growing. The first-in-class therapy targeting BCL11A in sickle cell disease and transfusion-dependent beta-thalassemia remains the foundation. It works by reactivating fetal hemoglobin production, effectively bypassing the disease-causing adult hemoglobin variant.
Beyond that, several therapies have advanced through late-stage trials and are in various stages of regulatory review or recent approval, including approaches targeting transthyretin amyloidosis, hereditary angioedema, and a small number of inherited eye diseases. Each works through a different mechanism — some through gene knockdown, others through correction or insertion — but all share the underlying CRISPR architecture.
What's in late-stage trials
The deeper pipeline is broader. Active late-stage clinical trials cover, in rough order of how close they are to approval:
Cardiovascular conditions. Therapies that durably reduce LDL cholesterol or other cardiovascular risk factors through one-time editing of liver targets are in advanced trials. The clinical question is not whether they reduce LDL — the data is striking — but the long-term safety of permanent gene modification in otherwise healthy people. Cardiology centers are watching closely.
Inherited metabolic disorders. Several disorders that result from single-gene defects in the liver are good candidates for in vivo CRISPR editing, where the therapy is delivered systemically rather than via ex vivo cell modification. Trials are underway across multiple metabolic indications.
Hereditary blindness. Building on the success of earlier gene therapies for inherited retinal diseases, CRISPR-based corrections are being studied for several inherited eye conditions.
Cancer immunotherapies. CAR-T therapies modified using CRISPR — to enhance persistence, reduce exhaustion, or enable allogeneic ("off-the-shelf") products — are in active trials in hematologic malignancies. This is a particularly fast-moving area.
The official trial registry at clinicaltrials.gov tracks all of these. Coverage of this work in STAT News has been particularly thorough for clinicians who want sustained reporting.
What physicians outside genetic medicine should know
Three things matter even for physicians who will not directly prescribe these therapies.
They are expensive, and access is uneven. First-in-class CRISPR therapies have launched at price points in the multi-million-dollar range per treatment. The clinical benefit can be transformative, but the access reality is sharply unequal across health systems and geographies. Cost coverage is being negotiated in patchwork ways.
Long-term safety data is still accruing. A one-time treatment that permanently edits the genome of certain cells is, by definition, long-term in its effects. The first cohort of treated patients is being followed for decades. Early safety signals have been favorable, but the field is appropriately careful about claims that extend beyond what the follow-up data supports.
Patient referral pathways are still maturing. For many of the conditions where CRISPR therapies are being approved, the bottleneck is not the therapy itself but identifying the patients who could benefit. Genetic testing access, specialist referral, and the logistics of treatment at concentrated centers of expertise — all of these are still being built out.
The ED-relevant edge cases
Most physicians' direct contact with CRISPR-treated patients will, for the foreseeable future, be incidental. A patient with sickle cell disease who has been treated and presents to the ED with an unrelated complaint. A patient on long-term observation after gene therapy who has questions about a fever. (For an adjacent neurotech-clinical reality check, see our piece on brain-computer interfaces in 2026.)
Two practical points:
1. Treatment history matters for differential. A sickle-cell patient who has received curative gene therapy may not have the same vaso-occlusive presentation as an untreated patient. Knowing the treatment history changes the differential meaningfully. 2. Specialist consultation thresholds are low. For any patient with a complex genetic-therapy history presenting with an unusual or systemic complaint, early consultation with the treating center is prudent. The relevant specialty teams are usually accessible and prefer being looped in early.
What's coming next
Three developments to watch over the next 12–24 months.
Base editing and prime editing approvals. These second-generation CRISPR technologies — which can change individual nucleotides without cutting the DNA backbone — are advancing through trials. The first approvals are expected within the next two years and may broaden the range of correctable conditions substantially.
Allogeneic ("off-the-shelf") cell therapies. Most current cell-based CRISPR therapies are autologous, requiring patient-specific manufacturing that limits scale. Allogeneic approaches in the cancer immunotherapy space are advancing and could meaningfully change cost and access.
Broadened insurance and policy coverage. As cumulative clinical evidence grows and more therapies receive approval, payer coverage decisions will move from individual cases to category policies. The BMJ has covered the policy and access dimensions of this carefully.
The honest summary
CRISPR clinical therapies in 2026 are not yet a routine part of most physicians' practice. They are, however, no longer experimental for a small but growing set of conditions. The technology is mature enough that medicine has to think about it as part of the diagnostic and therapeutic landscape — not as a future possibility, but as a present reality for specific patient populations.
For most clinicians, the practical implication is awareness: knowing which conditions have approved or near-approved CRISPR therapies, knowing where to refer patients who might benefit, and being prepared for an inflection in the next five years that will make this technology meaningfully more visible in everyday practice.
